LivaNova PLC initiated the commercial launch of its Essenz™ Perfusion System in China, marking a significant expansion into the company's second-largest market for heart-lung machines (HLMs) after the United States. The Essenz Perfusion System recently received regulatory approval from China’s National Medical Products Administration (NMPA). This system is designed to enable patient-tailored perfusion and improve clinical workflows during cardiopulmonary bypass procedures.
China's cardiac surgery landscape is rapidly developing, with over 700 hospitals capable of performing cardiac surgery and projections for approximately 185,000 adult and 23,500 pediatric extracorporeal circulation procedures in 2025. The Essenz system, which has already supported over 100,000 patients worldwide since its February 2023 launch, offers enhanced ergonomics, information, and control for perfusionists and surgeons.
This launch is expected to provide perfusionists and surgeons in China with advanced technology, delivering better results for patients and enhancing the level of care throughout the country. It represents a strategic move to capitalize on a growing market with significant unmet needs in cardiovascular disease, driving future revenue.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.